.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
McKesson
Fuji
Cantor Fitzgerald
Medtronic
Healthtrust
Novartis
Daiichi Sankyo
QuintilesIMS
Colorcon

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:System for treatment and imaging using ultrasonic energy and microbubbles and related method thereof
Abstract: A method and related system for providing therapy to a treatment site, such as stenosis or other vasculature disease, at one or more locations of a subject, such as the vasculature. The method includes: advancing an ultrasound catheter to or in proximity to the subject\'s treatment site; infusing microbubbles into or proximal to the treatment site; and delivering ultrasonic energy from the ultrasound catheter. The ultrasonic energy may be adapted for: imaging the treatment site, translating the microbubbles into or in the vicinity of the treatment site and/or rupturing the microbubbles.
Inventor(s): Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA)
Assignee: University of Virginia Patent Foundation (Charlottesville, VA)
Application Number:14/063,830
Patent Claims:1. A method of providing therapy to a treatment site of a subject, said method comprising: advancing an ultrasound catheter to or in proximity to the subject's treatment site, said catheter having a proximal region and distal region; infusing microbubbles from said distal region of said ultrasound catheter into or proximal to the treatment site; administering a thrombus lysing agent to the subject's treatment site; delivering therapeutic ultrasonic energy, during said infusing, from within said distal region of said ultrasound catheter to said microbubbles to move said microbubbles, thereby focally delivering said microbubbles to or in proximity to the subject's treatment site; and providing real time imaging of the microbubbles as they are infused, wherein said microbubbles remain intact and echogenic as they are delivered to or in proximity to the subject's treatment site and are real time imaged; wherein said real time imaging is provided by delivering imaging ultrasonic energy from within said distal region of said ultrasound catheter to the treatment site.

2. The method of claim 1, wherein said thrombus lysing agent comprises a thrombus lysing drug.

3. The method of claim 2, wherein said thrombus lysing drug is selected from the group consisting of: rt-PA, APSAC, TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase and pamiteplase.

4. The method of claim 1, wherein said thrombus lysing agent comprises a plasminogen activator.

5. The method of claim 1, wherein said providing real time imaging facilitates guidance of precise delivery of said microbubbles to the treatment site.

6. The method of claim 1, wherein the treatment site is in an artery and the thrombus lysing agent is administered intravenously.

7. The method of claim 1, wherein the thrombus lysing agent is administered from said distal region of said catheter.

8. The method of claim 7, wherein said thrombus lysing agent is administered side-by-side with the infusion of said microbubbles.

9. The method of claim 1 wherein the treatment site is in the cerebral vasculature.

10. The method of claim 9, wherein the treatment site is in a cerebral artery.

11. The method of claim 1, wherein the location of the focal delivery is guided by said real time imaging performed by an integral, real-time, coincident, ultrasound imaging system.

12. The method of claim 1, wherein the location of the focal delivery is guided by said real time imaging.

13. The method of claim 1, further comprising rupturing at least some of said microbubbles after moving said microbubbles to or in proximity to the subject's treatment site.

14. A system for providing therapy to a treatment site of a subject, the system comprising: a tubular member having a proximal region and distal region and a lumen, said distal region of said tubular member adapted to advance to or in proximity to the subject's treatment site; a microbubble reservoir in or in hydraulic communication with said lumen of said tubular member, said microbubble reservoir being adapted to release microbubbles that are intended to be located into or in proximity to the treatment site; a thrombus lysing agent for delivery to the subject's treatment site; a therapeutic ultrasound transducer at said distal region of said tubular member, said therapeutic ultrasound transducer configured to deliver therapeutic ultrasonic energy from within said distal region of said ultrasound catheter to said microbubbles to move, without rupturing, said microbubbles toward the treatment site; a port in fluid communication with said lumen and opening to an external surface of said tubular member, said port being configured to release said microbubbles in a direction toward said therapeutic ultrasound transducer; and an imaging component comprising an imaging ultrasound transducer configured to provide real time imaging of said microbubbles as they are moved, wherein said imaging ultrasound transducer is mounted relative to said therapeutic ultrasound transducer at said distal region of said tubular member such that the delivery of said therapeutic ultrasound energy is aligned with said real time imaging.

15. The system of claim 14, wherein said tubular member is configured to be inserted into the cerebral vasculature.

16. The system of claim 14, further comprising a conduit configured to intravenously deliver said thrombus lysing agent, wherein the treatment site is an artery and wherein said tubular member is configured to be inserted within the artery.

17. The system of claim 16, wherein the treatment site is in a cerebral artery and said tubular member is configured to be inserted within the cerebral artery.

18. The system of claim 14, wherein the treatment site is in the cerebral vasculature.

19. The system of claim 18, wherein the thrombus lysing agent is selected from the group consisting of: rt-PA, APSAC, TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase and pamiteplase.

20. The system of claim 14, wherein said therapeutic ultrasound transducer is further configured to deliver therapeutic ultrasonic energy from within said distal region of said ultrasound catheter to said microbubbles to rupture said microbubbles after moving said microbubbles toward the treatment site.

21. A method of providing therapy to a treatment site of a subject, said method comprising: advancing an ultrasound catheter to or in proximity to the subject's treatment site, said catheter having a proximal region and a distal region; infusing microbubbles from said distal region of said ultrasound catheter into or proximal to the treatment site; administering a thrombus lysing agent to the subject's treatment site; delivering therapeutic ultrasonic energy from within said distal region of said ultrasound catheter to said microbubbles to focally deliver said microbubbles to the treatment site; and delivering imaging ultrasonic energy from within said distal region of said ultrasound catheter to the treatment site to provide real time imaging of the treatment site; wherein the microbubbles are infused directionally toward a location from which said therapeutic ultrasonic energy is directed.

22. A method of providing therapy to a treatment site of a subject, said method comprising: advancing an ultrasound catheter to or in proximity to the subject's treatment site, said catheter having a proximal region and distal region; infusing therapeutic material from said distal region of said ultrasound catheter; delivering therapeutic ultrasonic energy from within said distal region of said ultrasound catheter to translate the therapeutic material so as to focally deliver said therapeutic material to the treatment site; and delivering imaging ultrasonic energy from within said distal region of said ultrasound catheter to the treatment site to provide real time imaging for guiding precise delivery of said therapeutic material to the treatment site.

23. The method of claim 22, further comprising controlling activation of said therapeutic ultrasonic energy.

24. The method of claim 22, wherein said treatment site comprises at least a portion of an organ.

25. The method of claim 24, wherein the organ is selected from the group consisting of: hollow organs, solid organs, parenchymal tissue, stromal tissue, and ducts.

26. The method of claim 22, wherein the treatment site comprises at least a portion of a tubular structure.

27. The method of claim 22, wherein said delivering therapeutic ultrasonic energy from said distal region of said ultrasound catheter to focally deliver said therapeutic material to the treatment site comprises delivering low frequency ultrasound energy to said therapeutic material.

28. The method of claim 22, wherein said therapeutic material is selected from the group consisting of: actinomycin-D, batimistat, c-myc antisense, dexamethasone, paclitaxel, taxanes, sirolimus, tacrolimus and everolimus, unfractionated heparin, low-molecular weight heparin, enoxaparin, bivalirudin, tyrosine kinase inhibitors, Gleevec, wortmannin, PDGF inhibitors, AG1295, rho kinase inhibitors, Y27632, calcium channel blockers, TRAM-34, IKCa channel blockers, amlodipine, nifedipine, and ACE inhibitors, S1P1 and/or S1P3 receptor antagonists, sphingosine kinase 1 inhibitors, synthetic polysaccharides, ticlopinin, dipyridamole, clopidogrel, fondaparinux, streptokinase, urokinase, r-urokinase, r-prourokinase, rt-PA, APSAC, TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase, pamiteplase, staphylokinase, abciximab, tirofiban, orbofiban, xemilofiban, sibrafiban, roxifiban, an anti-restenosis agent, an anti-thrombogenic agent, an antibiotic, an anti-platelet agent, an anti-clotting agent, an anti-inflammatory agent, an anti-neoplastic agent, a chelating agent, penicillamine, triethylene tetramine dihydrochloride, EDTA, DMSA (succimer) deferoxamine mesylate, a radiocontrast agent, a radio-isotope, a prodrug, antibody fragments, antibodies, gene therapy agents, viral vectors, and plasmid DNA vectors.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
ACTIVASE
alteplase
VIAL; SINGLE-USE1031720011987-11-13► Subscribe University of Virginia Patent Foundation (Charlottesville, VA) Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA) ► SubscribeRXsearch
Genentech
ACTIVASE
alteplase
VIAL; SINGLE-USE1031720021987-11-13► Subscribe University of Virginia Patent Foundation (Charlottesville, VA) Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA) ► SubscribeRXsearch
Genentech
CATHFLO ACTIVASE
alteplase
VIAL1031720031987-11-13► Subscribe University of Virginia Patent Foundation (Charlottesville, VA) Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA) ► SubscribeRXsearch
Centocor Inc
REOPRO
abciximab
INJECTABLE; INJECTION1035750011994-12-22► Subscribe University of Virginia Patent Foundation (Charlottesville, VA) Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA) ► SubscribeRXsearch
Ekr Therap
RETAVASE
reteplase
VIAL1037860011998-05-06► Subscribe University of Virginia Patent Foundation (Charlottesville, VA) Hossack; John A. (Charlottesville, VA), Wamhoff; Brian R. (Charlottesville, VA), Klibanov; Alexander L. (Charlottesville, VA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
US Army
Boehringer Ingelheim
Accenture
Fuji
Daiichi Sankyo
Julphar
Harvard Business School
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot